Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- US stocks on course for lower open as AI jitters hit Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% as attacks halt Saudi pipeline
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026 7:00 AM EDTPlanned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder
Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025
CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline... More
